Quality & complianceOfficial

Denmark flags aprepitant Stada supply problems expected to last until early March 2027

🇩🇰 DKMA · Thu 12 Nov 2026

DKMA says production problems at STADA Nordic ApS are disrupting supply of Aprepitant 'Stada' 125+80 mg hard capsules, with disruption forecast from late October 2026 to early March 2027.

The Danish Medicines Agency (DKMA) has published a supply notice reporting current problems with Aprepitant "Stada" 125+80 mg hard capsules, marketed in Denmark by STADA Nordic ApS. The notice is dated 12 November 2026.

DKMA gives the cause as production problems. The expected period of disruption runs from the end of October 2026 to the start of March 2027, which is roughly four months. The notice does not say whether supply will be partial or complete, nor does it quantify the shortfall.

The active substance is aprepitant, classified under ATC code A04AD12. Aprepitant is an antiemetic. The notice does not describe the clinical indications or recommend specific alternatives.

DKMA notes that it is possible to apply for a dispensing permit (udleveringstilladelse). Questions about the current status of supply should be directed to the company, according to the agency.

What it means for your team

  • Market-access and supply teams in Denmark should plan for the stated window of late October 2026 to early March 2027, and check the status directly with STADA Nordic ApS.
  • Regulatory affairs teams should note that DKMA points to the option of applying for a dispensing permit as a route to access.
  • Pharmacovigilance and quality teams may wish to track the production problems cited as the cause, although the notice gives no technical detail and no quality defect is reported.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →